157 related articles for article (PubMed ID: 31520102)
1. Skin platinum deposition in colorectal cancer patients following oxaliplatin-based therapy.
Cao Y; Chang Q; Zhang W; Ornatsky O; Hedley D; Chen EX
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1195-1200. PubMed ID: 31520102
[TBL] [Abstract][Full Text] [Related]
2. Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry.
Beijers AJ; Mols F; Tjan-Heijnen VC; Faber CG; van de Poll-Franse LV; Vreugdenhil G
Acta Oncol; 2015 Apr; 54(4):463-9. PubMed ID: 25417732
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of controlled-release oxycodone for oxaliplatin-induced peripheral neuropathy and the extension of FOLFOX therapy in advanced colorectal cancer patients.
Nagashima M; Ooshiro M; Moriyama A; Sugishita Y; Kadoya K; Sato A; Kitahara T; Takagi R; Urita T; Yoshida Y; Tanaka H; Oshiro T; Okazumi S; Katoh R
Support Care Cancer; 2014 Jun; 22(6):1579-84. PubMed ID: 24452412
[TBL] [Abstract][Full Text] [Related]
4. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
[TBL] [Abstract][Full Text] [Related]
5. [Reduction of oxaliplatin-related neurotoxicity by calcium and magnesium infusions].
Muto O; Ando H; Ono T; Itagaki H; Kobayashi Y; Onuki M; Akashi T; Tanaka Y; Hanaoka T
Gan To Kagaku Ryoho; 2007 Apr; 34(4):579-81. PubMed ID: 17431344
[TBL] [Abstract][Full Text] [Related]
6. Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity.
Milla P; Airoldi M; Weber G; Drescher A; Jaehde U; Cattel L
Anticancer Drugs; 2009 Jun; 20(5):396-402. PubMed ID: 19287306
[TBL] [Abstract][Full Text] [Related]
7. Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer.
Maindrault-Goebel F; Tournigand C; André T; Carola E; Mabro M; Artru P; Louvet C; de Gramont A
Ann Oncol; 2004 Aug; 15(8):1210-4. PubMed ID: 15277260
[TBL] [Abstract][Full Text] [Related]
8. A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration.
Beijers AJ; Mols F; Vreugdenhil G
Support Care Cancer; 2014 Jul; 22(7):1999-2007. PubMed ID: 24728618
[TBL] [Abstract][Full Text] [Related]
9. Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance).
Pachman DR; Qin R; Seisler DK; Smith EM; Beutler AS; Ta LE; Lafky JM; Wagner-Johnston ND; Ruddy KJ; Dakhil S; Staff NP; Grothey A; Loprinzi CL
J Clin Oncol; 2015 Oct; 33(30):3416-22. PubMed ID: 26282635
[TBL] [Abstract][Full Text] [Related]
10. Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV.
Vincenzi B; Frezza AM; Schiavon G; Spoto C; Silvestris N; Addeo R; Catalano V; Graziano F; Santini D; Tonini G
Support Care Cancer; 2013 May; 21(5):1313-9. PubMed ID: 23196819
[TBL] [Abstract][Full Text] [Related]
11. Oxaliplatin added to fluoropyrimidine for adjuvant treatment of colorectal cancer is associated with long-term impairment of peripheral nerve sensory function and quality of life.
Stefansson M; Nygren P
Acta Oncol; 2016; 55(9-10):1227-1235. PubMed ID: 27550718
[TBL] [Abstract][Full Text] [Related]
12. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.
Culy CR; Clemett D; Wiseman LR
Drugs; 2000 Oct; 60(4):895-924. PubMed ID: 11085200
[TBL] [Abstract][Full Text] [Related]
13. Hyperacute peripheral neuropathy is a predictor of oxaliplatin-induced persistent peripheral neuropathy.
Tanishima H; Tominaga T; Kimura M; Maeda T; Shirai Y; Horiuchi T
Support Care Cancer; 2017 May; 25(5):1383-1389. PubMed ID: 27921224
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR).
Maindrault-Goebel F; de Gramont A; Louvet C; André T; Carola E; Gilles V; Lotz JP; Tournigand C; Mabro M; Molitor JL; Artru P; Izrael V; Krulik M
Ann Oncol; 2000 Nov; 11(11):1477-83. PubMed ID: 11142489
[TBL] [Abstract][Full Text] [Related]
15. [Prevention of oxaliplatin-induced neuropathy by carbamazepine. A pilot study].
Eckel F; Schmelz R; Adelsberger H; Erdmann J; Quasthoff S; Lersch C
Dtsch Med Wochenschr; 2002 Jan; 127(3):78-82. PubMed ID: 11797144
[TBL] [Abstract][Full Text] [Related]
16. The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen.
Nishioka M; Shimada M; Kurita N; Iwata T; Morimoto S; Yoshikawa K; Higashijima J; Miyatani T; Kono T
Int J Clin Oncol; 2011 Aug; 16(4):322-7. PubMed ID: 21258836
[TBL] [Abstract][Full Text] [Related]
17. Clinical management of oxaliplatin-associated neurotoxicity.
Grothey A
Clin Colorectal Cancer; 2005 Apr; 5 Suppl 1():S38-46. PubMed ID: 15871765
[TBL] [Abstract][Full Text] [Related]
18. Preventive effect of traditional Japanese medicine on neurotoxicity of FOLFOX for metastatic colorectal cancer: a multicenter retrospective study.
Hosokawa A; Ogawa K; Ando T; Suzuki N; Ueda A; Kajiura S; Kobayashi Y; Tsukioka Y; Horikawa N; Yabushita K; Fukuoka J; Sugiyama T
Anticancer Res; 2012 Jul; 32(7):2545-50. PubMed ID: 22753712
[TBL] [Abstract][Full Text] [Related]
19. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
Tournigand C; Cervantes A; Figer A; Lledo G; Flesch M; Buyse M; Mineur L; Carola E; Etienne PL; Rivera F; Chirivella I; Perez-Staub N; Louvet C; André T; Tabah-Fisch I; de Gramont A
J Clin Oncol; 2006 Jan; 24(3):394-400. PubMed ID: 16421419
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of bevacizumab with modified OPTIMOX1 as first-line therapy for metastatic colorectal cancer: the TCOG-GI 0802 study.
Nakayama N; Sato A; Tanaka S; Shimada K; Konishi K; Sasaki E; Hibi K; Ichikawa H; Kikuchi Y; Sakuyama T; Sekikawa T; Hayashi K; Nishina H;
Invest New Drugs; 2015 Aug; 33(4):954-62. PubMed ID: 25937430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]